Dose-Ranging Study for Prolonged Postoperative Analgesia in Subject Undergoing Total Knee Arthroplasty

NCT00485693 | Completed Phase 2 Results

• 1 other identifier: SKY0402C208
• Study Type: interventional
• Target: 138
• Locations: 2 countries
• Sites: 9

Brief Summary

Dose-ranging study for prolonged postoperative analgesia in subjects undergoing total knee arthroplasty

Conditions

Postoperative Pain

Keywords

pain; postoperative; total knee arthroplasty; analgesia

Outcome Measures

Primary Outcomes (1)

• Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores Through Postoperative Day 4

  The subject's pain intensity was to be assessed with activity (NRS-A) after actively flexing the involved knee to the maximum flexion point possible. The subject was asked to respond to the following question: "On a scale of 0 to 10, where 0 = no pain and 10 = worst possible pain, how much pain did you have while bending your knee?"

  0 to 96 hours

Secondary Outcomes (1)

• Number of Participants With Adverse Events or Serious Adverse Events Through 30 Days

  Up to 30 days

Study Arms (2)

Bupivacaine HCl

ACTIVE COMPARATOR

Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)

Drug: Bupivacaine HCl

SKY0402

OTHER

SKY0402 at various dosage levels. Single administration.

Drug: SKY0402

Interventions

Bupivacaine HCl DRUG

150 mg Bupivacaine HCl

Also known as: Bupivacaine HCl (Marcaine 0.25% with epinephrine 1:200,000)

Bupivacaine HCl

SKY0402 DRUG

600 mg SKY0402 (study drug)

Also known as: EXPAREL

SKY0402

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female, greater than or equal to 18 and less than or equal to 75 years of age at the Screening Visit.
• Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
• Scheduled to undergo primary unilateral total knee arthroplasty (TKA) under general anesthesia.
• American Society of Anesthesiology (ASA) Physical Class 1-3.
• Able and willing to comply with all study visits and procedures.
• Able to speak, read, and understand the language of the Informed Consent, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
• Willing and capable of providing written informed consent.

You may not qualify if:

• Pregnancy, nursing, or planning to become pregnant during the study or within one month after dosing.
• Use of any of the following medications within the times specified before surgery:
• Long-acting opioid medication within 3 days.
• Any opioid medication within 24 hours.
• Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site administered study treatment, and which may confound the postoperative assessments (e.g., significant pain from other joints, chronic neuropathic pain, concurrent contralateral TKA, concurrent foot surgery, etc.).
• Body weight less than 50 kilograms (110 pounds) or morbid obesity.
• Contraindication to any of the pain-control agents planned for postoperative use (e.g., acetaminophen, morphine, oxycodone, ketorolac).
• Contraindication to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
• Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject's participation in this study.
• History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
• Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
• Current or historical evidence of any clinically significant disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course.
• Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.
• In addition, the subject will be ineligible to receive study drug if he or she meets the following criteria during surgery:
• Any clinically significant event or condition uncovered during surgery(e.g., excessive bleeding), which occurs before study drug administration, that might render the subject medically unstable or complicate the subject's postoperative course.

Sponsors & Collaborators

• Pacira Pharmaceuticals, Inc: lead

Study Sites (9)

West Alabama Research, Inc.

Birmingham, Alabama, 35209, United States

Location

California Clinical Research, Inc.

Davis, California, 95616, United States

Location

Accurate Clinical Trials, Inc.

Laguna Hills, California, 92653, United States

Location

St. Luke's Roosevelt Hospital

New York, New York, 10019, United States

Location

The Ohio State University Medical Center

Columbus, Ohio, 43220, United States

Location

Texas Tech University Health Science Center

Lubbock, Texas, 79430, United States

Location

Urazova Nemocnice Brno

Brno, 66250, Czechia

Location

Regional Hospital Kladno

Kladno, 1548, Czechia

Location

The Hospital Trebic

Třebíč, 67401, Czechia

Location

Related Publications (1)

• Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3.

  PMID: 22900785 DERIVED

MeSH Terms

Conditions

Pain, Postoperative; Pain; Agnosia

Interventions

Bupivacaine; Epinephrine

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Neurologic Manifestations; Signs and Symptoms; Perceptual Disorders; Neurobehavioral Manifestations; Nervous System Diseases

Intervention Hierarchy (Ancestors)

Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines; Ethanolamines; Amino Alcohols; Alcohols; Biogenic Monoamines; Biogenic Amines; Catecholamines; Catechols; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons

Results Point of Contact

• Title: Executive Medical Director
• Organization: Pacira Pharmaceuticals, Inc.

ErolOnel@pacira.com

203-837-6500

Study Officials

• Joyce Davis, RN

  Pacira Pharmaceuticals, Inc

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 11, 2007
• First Posted: June 13, 2007
• Study Start: June 1, 2007
• Primary Completion: August 1, 2009
• Study Completion: August 1, 2009
• Last Updated: June 28, 2022
• Results First Posted: August 6, 2013

Record last verified: 2022-06

Locations

US (6); CZ (3)